15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering biote Corp, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $1.50 to $4.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $2.50 sits 64% above the current $1.52. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.09 next quarter toward $0.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to biote Corp.
As of Sep, 2 of 3 firms rate BTMD a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BTMD EPS & revenue forecast
EPS · NEXT QUARTER
$0.09
Range $0.09 – $0.09 · 1 analysts · +28% YoY
Next period, 1 analysts expect biote Corp to earn $0.09 a share (range $0.09 – $0.09), versus $0.07 a year earlier. Full-year consensus is $0.35, growing to $0.45 the year after.
REVENUE · NEXT QUARTER
$44.1M
Range $43.4M – $45.4M · 1 analysts · -5% YoY
Revenue is expected to reach $44.1M (range $43.4M – $45.4M), -5.0% year-over-year. Full-year consensus is $177.9M, rising to $187.6M next year.
Top analysts covering biote Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BTMD.
#1
Jeff Van Sinderen
B. Riley Securities · Rank #81
Hold
$1.50-1.3% to target
Overall win rate
44%
+ Follow
#2
JK
Jonna Kim
TD Cowen
Buy
$2.00+31.6% to target
Coverage
—
+ Follow
#3
AF
Alex Fuhrman
Craig-Hallum
Buy
$8.00+426.3% to target
Coverage
—
+ Follow
#4
GF
Gregory Fraser
Truist Securities
Buy
$4.00+163.2% to target
Coverage
—
+ Follow
#5
Kaumil Gajrawala
Jefferies
Buy
$5.92+289.5% to target
Coverage
—
+ Follow
BTMD stock forecast FAQ
What is BTMD's average 12-month price target?+
The 3 analysts with a live target average $2.50 for biote Corp over the next 12 months, ranging from a $4.00 high to a $1.50 low.
Is BTMD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BTMD?+
The Street-high target is $4.00 (Truist Securities), and the Street-low is $1.50 (B. Riley Securities). The average of all 3 active targets is $2.50.
How many Wall Street analysts cover BTMD?+
3 analysts have an active rating on biote Corp, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering BTMD?+
Among analysts who currently cover BTMD, Jeff Van Sinderen of B. Riley Securities has the strongest overall Quantellect track record (Rank #81). Their current call is Hold with a $1.50 target.
What is biote Corp's projected EPS for next quarter?+
The consensus estimate is $0.09 per share (range $0.09 – $0.09) across 1 analysts. Full-year EPS is projected at $0.35, rising to $0.45 the following year.
How much revenue is biote Corp expected to report next quarter?+
Consensus revenue is $44.1M (range $43.4M – $45.4M). Full-year revenue is projected at $177.9M, growing to $187.6M next year.
Have analysts been upgrading or downgrading BTMD lately?+
As of Sep, 2 of 3 firms rate BTMD a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BTMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
